Login / Signup

Risk-benefit analysis of primary prophylaxis against Pneumocystis jirovecii pneumonia in patients with rheumatic diseases receiving rituximab.

Jun Won ParkJeffrey R CurtisSe Rim ChoiMin Jung KimYou-Jung HaEun Ha KangYun Jong LeeEun Bong Lee
Published in: Arthritis & rheumatology (Hoboken, N.J.) (2023)
The benefit associated with primary PJP prophylaxis overweighs the risk of severe AEs in patients receiving rituximab and concomitant high-dose glucocorticoid treatment. This article is protected by copyright. All rights reserved.
Keyphrases
  • high dose
  • diffuse large b cell lymphoma
  • low dose
  • hodgkin lymphoma
  • chronic lymphocytic leukemia
  • stem cell transplantation
  • acute respiratory distress syndrome